Through its research division, Juva research scientists are evaluating an internally curated database of compounds found in the cannabis plant for their therapeutic benefit. The news follows the Company’s identification of non-cannabinoid compound JUVA-019, which the Company has filed a patent upon and also begun further preclinical research. In recent months, Juva has been developing a chemical library of natural and semi-synthetic non-cannabinoids found in the cannabis plant with the intention of identifying compounds with anti-inflammatory properties, with the first compound being identified as JUVA-019. Juva’s hypothesis is that the therapeutic potential of cannabis is widely known, yet the cause of the overarching medical benefits of cannabis is mostly undefined. While many speculate that cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD) interacting with the endocannabinoid system are the cause of the benefit, Juva is taking a chemical approach to the research, looking further into the compounds present in the plant beyond cannabinoids that may have the benefit. As such, the Juva research team has built an extensive database of less studied compounds that it continues to evaluate for their anti-inflammatory potential, now having two compounds in its clinical pipeline: JUVA-019 and JUVA-041.
“Juva is a unique company in that we are leveraging our cannabis expertise to vertically integrate value-building science,” said
JUVA-019 and JUVA-041 are now designated as lead compounds. The Company plans to conduct comparative studies on the candidates to determine if combining them with other cannabinoid or non-cannabinoid compounds increases the efficacy of the anti-inflammatory mode of action. Based on those results, Juva will either move forward with the standalone compounds, or the newly discovered, more effective formulations. After said results, the candidates will be developed in a 2-prong approach. The natural chemophores will be advanced unmodified and evaluated for select applications in the consumer nutraceutical and wellness categories. In parallel, standard medicinal chemistry tools will be applied to improve upon potency and absorption, distribution, metabolism, and excretion (ADME) properties. The compounds will be advanced through a standard pharma development stage/gate plan, beginning with profiling in industry-standard in vitro and in vivo models of inflammatory disease. This profile is necessary to attract the attention of larger pharmaceutical players who may be interested in the candidates for their own pipelines. The Company anticipates initiating non-clinical development within the next 6-9 months. This combined consumer and medical strategy reduces development cost, risk, and time, and creates an opportunity for Juva to unlock shareholder value sooner than other pharmaceutical competitors.
ON BEHALF OF THE BOARD,
-
inquiries@juvalife.com
About
For further information, please contact:
Juva Life Investor Relations
Tel: +1 833-333-5882 (JUVA)
Email: inquiries@juvalife.com
Forward Looking Statement
This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.
Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended
The CSE does not accept responsibility for the adequacy or accuracy of this release.
Source:
2021 GlobeNewswire, Inc., source